These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19279447)

  • 1. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
    Papendorp SG; van den Berk GE
    AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
    [No Abstract]   [Full Text] [Related]  

  • 2. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir treatment response in an HIV-2 infected patient: a case report.
    Garrett N; Xu L; Smit E; Ferns B; El-Gadi S; Anderson J
    AIDS; 2008 May; 22(9):1091-2. PubMed ID: 18520356
    [No Abstract]   [Full Text] [Related]  

  • 5. [Integrase inhibition--a new mode of action in HIV therapy].
    van Lunzen J; Degen O
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
    [No Abstract]   [Full Text] [Related]  

  • 6. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 7. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir--beauty and the beast. Both the advantages and the limitations of this integrase inhibitor were evident this year.
    Albrecht H
    J Watch AIDS Clin Care; 2010 Jan; 22(1):4. PubMed ID: 20626067
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
    Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
    Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
    Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
    J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltegravir susceptibility and fitness progression of HIV type-1 integrase in patients on long-term antiretroviral therapy.
    Buzón MJ; Marfil S; Puertas MC; Garcia E; Clotet B; Ruiz L; Blanco J; Martinez-Picado J; Cabrera C
    Antivir Ther; 2008; 13(7):881-93. PubMed ID: 19043922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
    Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV agents. Integrase inhibitor raltegravir makes its mark.
    TreatmentUpdate; 2007 Feb; 19(2):8-9. PubMed ID: 17447316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.